Lakefront Biotherapeutics NV (GLPGF)
Lakefront Biotherapeutics NV is a biotechnology company focused on developing medicines in oncology and immunology, with research activities primarily in the United States and Europe. Its pipeline includes GLPG3667, which is being studied in phase 2 trials for dermatomyositis and systemic lupus erythematosus, as well as GLPG5101, a CD19 CAR-T candidate in phase 1/2 testing for relapsed or refractory non-Hodgkin lymphoma. The company is also advancing GLPG5301, a BCMA CAR-T candidate in phase 1/2 development for relapsed or refractory multiple myeloma. Lakefront Biotherapeutics maintains collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is based in Mechelen, Belgium. It was formerly known as Galapagos NV and adopted its current name in May 2026.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-GLPG.F
|
$29.46
|
4.9% Upside
|
Fair
|
—
|
—
|
—
|
Great
|
—
|
—
|
—
|
0.0%
|
August 10, 2026
|
3.5x
|
0.5x
|
1.6x
|
1.934 B
|
-1.484 B
|
0.4%
|
62.1%
|
39.2
|
—
|
-63.6%
|
